Shots:
- RemeGen has granted Santen exclusive rights to develop, manufacture, & commercialize RC28-E in Greater China (incl. Mainland China, Hong Kong, Macau, & Taiwan), South Korea, Thailand, Vietnam, Singapore, Philippines, Indonesia, & Malaysia, while RemeGen will retain its rights in other territories
- As per the deal, RemeGen will receive $38.9M (¥250M) upfront, ~$72.3M (¥520M) in development & regulatory milestones plus ~$73M (¥525M) in sales milestones, with net sales-based tiered royalties in Santen-licensed areas
- RC28-E, a dual-target VEGF/FGF fusion protein, showed significant BCVA gains & CST reduction in a P-II trial for diabetic macular edema presented at ARVO 2025; the NMPA’s BLA submission for DME & wAMD are planned in H2’25 & mid-2026, respectively
Ref: PRnewswire | Image: Santen Pharmaceutical & RemeGen| Press Release
Related News:- Vor Bio Enters a ~$4.12B Exclusive Global License Agreement with RemeGen to Develop and Commercialize Telitacicept
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
